Exelixis Inc. (EXEL)
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
Exelixis, Inc. ( EXEL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO, President & Director Christopher Senner - Executive VP & CFO Dana Aftab - Executive Vice President of Research & Development P. Haley - Executive Vice President of Commercial Conference Call Participants Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Anastasia Parafestas - Jefferies LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.47 per share a year ago.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm.
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Citi's Biopharma Back to School Conference September 3, 2025 3:15 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thank you for being here today at the 2025 Citi Biopharma Conference in Boston. Happy to have with us this afternoon.
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Exelixis, Inc. (NASDAQ:EXEL ) 2025 Wells Fargo Healthcare Conference September 3, 2025 12:45 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the first session after lunch time.
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
